Wernersson, S. & Pejler, G. Mast cell secretory granules: armed for battle. Nat. Rev. Immunol. 14, 478–494 (2014).
Siebenhaar, F., Redegeld, F. A., Bischoff, S. C., Gibbs, B. F. & Maurer, M. Mast cells as drivers of disease and therapeutic targets. Trends Immunol. 39, 151–162 (2018).
Frossi, B., Mion, F., Tripodo, C., Colombo, M. P. & Pucillo, C. E. Rheostatic functions of mast cells in the control of innate and adaptive immune responses. Trends Immunol. 38, 648–656 (2017).
Caughey, G. H. Mast cell proteases as pharmacological targets. Eur. J. Pharm. 778, 44–55 (2016).
Pejler, G., Abrink, M., Ringvall, M. & Wernersson, S. Mast cell proteases. Adv. Immunol. 95, 167–255 (2007).
Pejler, G. The emerging role of mast cell proteases in asthma. Eur. Respir. J. 54, 1900685 (2019).
Berger, P. et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J. Appl Physiol. 91, 1372–1379 (2001).
Cairns, J. A. & Walls, A. F. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest 99, 1313–1321 (1997).
Woodman, L. et al. Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-β1. J. Immunol. 181, 5001–5007 (2008).
Maun, H. R. et al. An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma. Cell 179, 417–431.e419 (2019).
Cairns, J. A. Inhibitors of mast cell tryptase beta as therapeutics for the treatment of asthma and inflammatory disorders. Pulm. Pharm. Ther. 18, 55–66 (2005).
Rawlings, N. D. et al. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res. 46, D624–D632 (2017).
Le, Q. T. et al. Processing of human protryptase in mast cells involves cathepsins L, B, and C. J. Immunol. 187, 1912–1918 (2011).
Schwartz, L. B. & Bradford, T. R. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J. Biol. Chem. 261, 7372–7379 (1986).
Addington, A. K. & Johnson, D. A. Inactivation of human lung tryptase: Evidence for a re-activatable tetrameric intermediate and active monomers. Biochemistry 35, 13511–13518 (1996).
Ren, S., Sakai, K. & Schwartz, L. B. Regulation of human mast cell β-tryptase: Conversion of inactive monomer to active tetramer at acid pH. J. Immunol. 160, 4561–4569 (1998).
Schechter, N. M., Choi, E. J., Selwood, T. & McCaslin, D. R. Characterization of three distinct catalytic forms of human tryptase-β: their interrelationships and relevance. Biochemistry 46, 9615–9629 (2007).
Hallgren, J., Lindahl, S. & Pejler, G. Structural requirements and mechanism for heparin-dependent activation and tetramerization of human βI- and βII-tryptase. J. Mol. Biol. 345, 129–139 (2005).
Maun, H. R. et al. Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer. J. Biol. Chem. 293, 9614–9628 (2018).
Fajardo, I. & Pejler, G. Formation of active monomers from tetrameric human β-tryptase. Biochem J. 369, 603–610 (2003).
Fukuoka, Y. & Schwartz, L. B. Human β-tryptase: detection and characterization of the active monomer and prevention of tetramer reconstitution by protease inhibitors. Biochemistry 43, 10757–10764 (2004).
Fukuoka, Y. & Schwartz, L. B. Active monomers of human β-tryptase have expanded substrate specificities. Int. Immunopharmacol. 7, 1900–1908 (2007).
Franconi, G. M., Graf, P. D., Lazarus, S. C., Nadel, J. A. & Caughey, G. H. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J. Pharm. Exp. Ther. 248, 947–951 (1989).
Gruber, B. L. et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J. Clin. Invest 84, 1657–1662 (1989).
Maier, M., Spragg, J. & Schwartz, L. B. Inactivation of human high molecular weight kininogen by human mast cell tryptase. J. Immunol. 130, 2352–2356 (1983).
Schiemann, F. et al. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. J. Immunol. 183, 2223–2231 (2009).
Schwartz, L. B., Bradford, T. R., Littman, B. H. & Wintroub, B. U. The fibrinogenolytic activity of purified tryptase from human lung mast cells. J. Immunol. 135, 2762–2767 (1985).
Pereira, P. J. et al. Human β-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 392, 306–311 (1998).
Sommerhoff, C. P. et al. The structure of the human βII-tryptase tetramer: Fo(u)r better or worse. Proc. Natl. Acad. Sci. USA 96, 10984–10991 (1999).
Hallgren, J., Backstrom, S., Estrada, S., Thuveson, M. & Pejler, G. Histidines are critical for heparin-dependent activation of mast cell tryptase. J. Immunol. 173, 1868–1875 (2004).
Fukuoka, Y. & Schwartz, L. B. The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized β-tryptase to form monomers that are inactive at neutral pH and active at acidic pH. J. Immunol. 176, 3165–3172 (2006).
Alter, S. C., Kramps, J. A., Janoff, A. & Schwartz, L. B. Interactions of human mast cell tryptase with biological protease inhibitors. Arch. Biochem Biophys. 276, 26–31 (1990).
Paesen, G. C. et al. A tick protein with a modified Kunitz fold inhibits human tryptase. J. Mol. Biol. 368, 1172–1186 (2007).
Sommerhoff, C. P. et al. A Kazal-type inhibitor of human mast cell tryptase: Isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis. Biol. Chem. Hoppe Seyler 375, 685–694 (1994).
Stubbs, M. T. et al. The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin. Implications for the structure of human mast cell tryptase and its inhibition. J. Biol. Chem. 272, 19931–19937 (1997).
Rothemund, S., Sonnichsen, F. D. & Polte, T. Therapeutic potential of the peptide leucine arginine as a new nonplant Bowman-Birk-like serine protease inhibitor. J. Med Chem. 56, 6732–6744 (2013).
Murakami, Y. et al. Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J. Nat. Prod. 65, 259–261 (2002).
Avrutina, O. et al. Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis. Chembiochem 9, 33–37 (2008).
Sommerhoff, C. P. et al. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β. J. Mol. Biol. 395, 167–175 (2010).
Thongyoo, P., Bonomelli, C., Leatherbarrow, R. J. & Tate, E. W. Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J. Med Chem. 52, 6197–6200 (2009).
Scarpi, D., McBride, J. D. & Leatherbarrow, R. J. Inhibition of human beta-tryptase by Bowman-Birk inhibitor derived peptides: creation of a new tri-functional inhibitor. Bioorg. Med Chem. 12, 6045–6052 (2004).
McGrath, M. E. et al. Structure-guided design of peptide-based tryptase inhibitors. Biochemistry 45, 5964–5973 (2006).
Ni, W. W., Cao, M. D., Huang, W., Meng, L. & Wei, J. F. Tryptase inhibitors: a patent review. Expert Opin. Ther. Pat. 27, 919–928 (2017).
Qian, X., Zheng, B., Burke, B., Saindane, M. T. & Kronenthal, D. R. A stereoselective synthesis of BMS-262084, an azetidinone-based tryptase inhibitor. J. Org. Chem. 67, 3595–3600 (2002).
Sutton, J. C. et al. Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg. Med Chem. Lett. 12, 3229–3233 (2002).
Wright, C. D. et al. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737). Biochem Pharm. 58, 1989–1996 (1999).
Costanzo, M. J. et al. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of new spirocyclic piperidine amide derivatives. Bioorg. Med Chem. Lett. 18, 2114–2121 (2008).
Krishna, M. T. et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol. 107, 1039–1045 (2001).
Ganesan, R., Eigenbrot, C. & Kirchhofer, D. Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem J. 430, 179–189 (2010).
Maun, H. R. et al. Bivalent antibody pliers inhibit beta-tryptase by an allosteric mechanism dependent on the IgG hinge. Nat. Commun. 11, 6435 (2020).
Rhee, H. et al. Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma. Allergy 79, 2993–3004 (2024).
Hartley, B. S. Homologies in serine proteinases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 257, 77–87 (1970).
Ereno-Orbea, J. et al. Structural basis of enhanced crystallizability induced by a molecular chaperone for antibody antigen-binding fragments. J. Mol. Biol. 430, 322–336 (2018).
Huber, R. & Bode, W. Structural basis of the activation and action of trypsin. Acc. Chem. Res 11, 114–122 (1978).
Cook, K. M., McNeil, H. P. & Hogg, P. J. Allosteric control of betaII-tryptase by a redox active disulfide bond. J. Biol. Chem. 288, 34920–34929 (2013).
Bush-Pelc, L. A. et al. Important role of the cys-191 cys-220 disulfide bond in thrombin function and allostery. J. Biol. Chem. 282, 27165–27170 (2007).
Miyata, T. et al. Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571–Ser substitution. Proc. Natl. Acad. Sci. USA 86, 8319–8322 (1989).
Ganesan, R. et al. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. Structure 17, 1614–1624 (2009).
Schaefer, M., Buchmueller, A., Dittmer, F., Strassburger, J. & Wilmen, A. Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI. J. Mol. Biol. 431, 4817–4833 (2019).
Jiang, L. et al. Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J. 449, 161–166 (2013).
Katschke, K. J. Jr. et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 287, 12886–12892 (2012).
Koschubs, T. et al. Allosteric antibody inhibition of human hepsin protease. Biochem J. 442, 483–494 (2012).
Chavarria-Smith, J. et al. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis. Sci. Transl. Med 14, eabp9159 (2022).
Mossner, E. et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115, 4393–4402 (2010).
Liang, W. C. et al. Dramatic activation of an antibody by a single amino acid change in framework. Sci. Rep. 11, 22365 (2021).
Fu, Z., Akula, S., Thorpe, M. & Hellman, L. Highly selective cleavage of TH2-promoting cytokines by the human and the mouse mast cell tryptases, indicating a potent negative feedback loop on TH2 immunity. Int. J. Mol. Sci. 20, 5147 (2019).
Gerhardy, S. et al. Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration. Nat. Commun. 13, 5222 (2022).
Walters, B. T., Ricciuti, A., Mayne, L. & Englander, S. W. Minimizing back exchange in the hydrogen exchange-mass spectrometry experiment. J. Am. Soc. Mass Spectrom. 23, 2132–2139 (2012).
Kan, Z. Y., Ye, X., Skinner, J. J., Mayne, L. & Englander, S. W. ExMS2: an Integrated Solution for Hydrogen-Deuterium Exchange Mass Spectrometry Data Analysis. Anal. Chem. 91, 7474–7481 (2019).
Walters, B. T., Mayne, L., Hinshaw, J. R., Sosnick, T. R. & Englander, S. W. Folding of a large protein at high structural resolution. Proc. Natl. Acad. Sci. USA 110, 18898–18903 (2013).
Walters, B. T. Empirical method to accurately determine peptide-averaged protection factors from hydrogen exchange MS data. Anal. Chem. 89, 1049–1053 (2017).
Masson, G. R. et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Nat. Methods 16, 595–602 (2019).
Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36–51 (2005).
Iudin, A. et al. EMPIAR: the electron microscopy public image archive. Nucleic Acids Res. 51, D1503–D1511 (2023).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D. Struct. Biol. 74, 519–530 (2018).
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D. Struct. Biol. 74, 531–544 (2018).
The PyMOL Molecular Graphics System, Version 3.1.3 Schrödinger, LLC.